See more : Samudera Shipping Line Ltd (S56.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Genmab A/S (GMAB.CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genmab A/S, a leading company in the Biotechnology industry within the Healthcare sector.
- Capital Metals plc (CMET.L) Income Statement Analysis – Financial Results
- The City Pub Group plc (CPC.L) Income Statement Analysis – Financial Results
- Beijing North Star Company Limited (BEIJF) Income Statement Analysis – Financial Results
- The Trade Desk, Inc. (0LF5.L) Income Statement Analysis – Financial Results
- Seagate Technology Holdings plc (STX) Income Statement Analysis – Financial Results
Genmab A/S (GMAB.CO)
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.47B | 14.60B | 8.48B | 10.11B | 5.37B | 3.03B | 2.37B | 1.82B | 1.13B | 850.39M | 663.57M | 484.64M | 350.94M | 582.08M | 586.08M | 745.11M | 529.54M | 135.55M | 98.51M | 4.10M | 68.33M | 0.00 |
| Cost of Revenue | 226.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 532.51M | 582.51M | 0.00 | 48.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.25B | 14.60B | 8.48B | 10.11B | 5.37B | 3.03B | 2.37B | 1.82B | 1.13B | 850.39M | 663.57M | 484.64M | -181.57M | -435.00K | 586.08M | 696.30M | 529.54M | 135.55M | 98.51M | 4.10M | 68.33M | 0.00 |
| Gross Profit Ratio | 98.63% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -51.74% | -0.07% | 100.00% | 93.45% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 7.63B | 5.56B | 4.18B | 3.14B | 2.39B | 1.43B | 874.28M | 660.88M | 487.66M | 505.68M | 527.58M | 536.70M | 0.00 | 0.00 | 935.36M | 1.42B | 618.50M | 359.95M | 304.10M | 373.33M | 345.98M | 396.23M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 661.00M | 342.00M | 213.70M | 146.99M | 102.41M | 91.22M | 79.53M | 66.74M | 64.61M | 67.85M | 160.25M | 148.75M | 143.53M | 38.59M | 37.11M | 38.04M | 72.04M | 64.55M | 86.85M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.30B | 2.68B | 1.28B | 661.00M | 342.00M | 213.70M | 146.99M | 102.41M | 91.22M | 79.53M | 66.74M | 64.61M | 67.85M | 160.25M | 148.75M | 143.53M | 38.59M | 37.11M | 38.04M | 72.04M | 64.55M | 86.85M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -176.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -221.18M | 309.57M | 210.70M | 184.29M | -882.55M | 0.00 | -42.91M |
| Operating Expenses | 10.93B | 8.24B | 5.46B | 3.80B | 2.73B | 1.64B | 1.02B | 763.29M | 402.66M | 585.21M | 594.32M | 601.32M | 67.85M | 160.25M | 1.08B | 1.35B | 966.67M | 607.76M | 526.43M | -437.17M | 410.54M | 440.17M |
| Cost & Expenses | 11.15B | 8.24B | 5.46B | 3.80B | 2.73B | 1.64B | 1.02B | 763.29M | 402.66M | 585.21M | 594.32M | 601.32M | 600.36M | 742.77M | 1.08B | 1.39B | 966.67M | 607.76M | 526.43M | -437.17M | 410.54M | 440.17M |
| Interest Income | 939.00M | 324.00M | 197.00M | 184.00M | 120.00M | 62.92M | 41.43M | 32.58M | 37.26M | 38.33M | 28.61M | 17.83M | 3.49M | 1.40M | 181.10M | 126.67M | 155.11M | 46.25M | 34.78M | 42.52M | 68.68M | 53.39M |
| Interest Expense | 27.00M | 21.00M | 13.00M | 10.00M | 7.00M | 417.00K | 2.80M | 213.00K | 118.00K | 4.05M | 3.33M | 2.72M | 43.09M | 39.65M | 25.05M | 220.83M | 1.15M | 1.03M | 1.35M | 68.58M | 83.71M | 100.37M |
| Depreciation & Amortization | 327.00M | 290.00M | 250.00M | 246.00M | 139.00M | 87.70M | 47.54M | 40.96M | 59.09M | 48.55M | 24.73M | -355.24M | -282.89M | -79.21M | -397.98M | -230.60M | 69.17M | 52.51M | 67.46M | -734.24M | 162.41M | 47.47M |
| EBITDA | 5.99B | 7.26B | 4.25B | 6.16B | 2.78B | 1.70B | 1.11B | 1.17B | 789.47M | 313.73M | 80.92M | -96.25M | -192.75M | -100.01M | -317.26M | -879.41M | -367.97M | -419.70M | -360.46M | -367.96M | -179.80M | 669.75M |
| EBITDA Ratio | 36.37% | 48.26% | 40.83% | 66.82% | 53.99% | 56.20% | 48.04% | 64.50% | 69.68% | 36.89% | 18.48% | -97.38% | -151.68% | -41.21% | -152.88% | -118.02% | -69.49% | -309.64% | -365.93% | -7,143.82% | -263.15% | 0.00% |
| Operating Income | 5.32B | 6.36B | 3.02B | 6.31B | 2.64B | 1.38B | 1.34B | 1.05B | 730.38M | 265.18M | 97.87M | -116.68M | -249.42M | -160.69M | -498.03M | -648.82M | -437.13M | -472.21M | -427.92M | 441.27M | -342.21M | 622.28M |
| Operating Income Ratio | 32.30% | 43.56% | 35.58% | 62.44% | 49.16% | 45.63% | 56.83% | 57.97% | 64.46% | 31.18% | 14.75% | -24.08% | -71.07% | -27.61% | -84.98% | -87.08% | -82.55% | -348.38% | -434.42% | 10,760.13% | -500.85% | 0.00% |
| Total Other Income/Expenses | 316.00M | 678.00M | 965.00M | -409.00M | 221.00M | 231.97M | -280.45M | 77.38M | 27.15M | 32.17M | -3.85M | 2.60M | 39.59M | 38.25M | 156.05M | -94.84M | 53.76M | 33.98M | 34.33M | -864.70M | 669.39M | -143.28M |
| Income Before Tax | 5.64B | 7.04B | 3.98B | 5.90B | 2.86B | 1.61B | 1.06B | 1.13B | 757.53M | 297.35M | 65.40M | -114.08M | -209.83M | -122.44M | -341.99M | -964.51M | -383.37M | -438.24M | -393.59M | 415.21M | 327.18M | 479.00M |
| Income Before Tax Ratio | 34.22% | 48.20% | 46.96% | 58.39% | 53.28% | 53.29% | 44.97% | 62.23% | 66.86% | 34.97% | 9.86% | -23.54% | -59.79% | -21.04% | -58.35% | -129.44% | -72.40% | -323.31% | -399.56% | 10,124.65% | 478.85% | 0.00% |
| Income Tax Expense | 1.29B | 1.51B | 975.00M | 1.15B | 693.00M | 139.83M | -39.83M | -56.86M | -5.99M | -3.95M | -4.75M | -2.63M | 5.92M | 20.87M | 5.91M | 583.00K | 54.91M | 35.01M | 35.69M | 42.52M | -66.00K | 326.00K |
| Net Income | 4.35B | 5.45B | 2.96B | 4.76B | 2.17B | 1.47B | 1.10B | 1.19B | 763.51M | 301.30M | 70.16M | -111.45M | -215.75M | -143.32M | -347.90M | -965.09M | -438.28M | -473.25M | -429.28M | 372.69M | 327.25M | 478.68M |
| Net Income Ratio | 26.42% | 37.36% | 34.86% | 47.06% | 40.37% | 48.66% | 46.65% | 65.36% | 67.39% | 35.43% | 10.57% | -23.00% | -61.48% | -24.62% | -59.36% | -129.52% | -82.77% | -349.14% | -435.79% | 9,087.83% | 478.95% | 0.00% |
| EPS | 66.64 | 83.38 | 46.00 | 73.00 | 34.40 | 24.03 | 18.14 | 19.83 | 13.05 | 5.35 | 1.38 | -2.42 | -4.80 | -3.19 | -7.75 | -21.62 | -9.97 | -12.16 | -13.73 | 14.08 | 14.33 | 21.43 |
| EPS Diluted | 66.02 | 82.59 | 45.54 | 72.22 | 34.04 | 23.73 | 17.77 | 19.22 | 12.56 | 5.26 | 1.35 | -2.42 | -4.80 | -3.19 | -7.75 | -21.62 | -9.97 | -12.16 | -13.73 | 14.08 | 14.33 | 21.43 |
| Weighted Avg Shares Out | 65.31M | 65.39M | 65.40M | 65.18M | 62.96M | 61.27M | 60.83M | 59.88M | 58.52M | 56.32M | 50.98M | 46.04M | 44.91M | 44.91M | 44.90M | 44.64M | 43.94M | 38.93M | 31.25M | 26.47M | 22.83M | 22.34M |
| Weighted Avg Shares Out (Dil) | 65.91M | 66.01M | 66.05M | 65.89M | 63.64M | 62.05M | 62.09M | 61.77M | 60.77M | 57.25M | 51.91M | 46.04M | 44.91M | 44.91M | 44.90M | 44.64M | 43.94M | 38.93M | 31.25M | 26.47M | 22.83M | 22.34M |
Source: https://incomestatements.info
Category: Stock Reports